E-B-FAHF-2, Multi OIT and Xolair for Food Allergy

New York Medical College (Other)
Overall Status
CT.gov ID
Icahn School of Medicine at Mount Sinai (Other)

Study Details

Study Description

Brief Summary

The purpose of this study is testing the use of Enhanced, Butanol purified Food Allergy Herbal Formula-2 (E-B-FAHF-2) Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.

Condition or Disease Intervention/Treatment Phase
  • Drug: Drug: Chinese Herbal Medication
  • Drug: Drug: Placebo
  • Drug: Drug: Omalizumab
Phase 2

Detailed Description

Prior studies have shown that this Chinese herbal formulation is safe and well-tolerated in food allergic individuals. While oral immunotherapy (OIT) can lead to desensitization, it remains uncertain whether this treatment can lead to lasting protection. Therefore, this study aims to use the Chinese herbal formula in combination with OIT to determine whether sustained protection can be achieved. All subjects will receive multi-allergen OIT, along with a 4 month course of omalizumab to provide added safety for the initial dose escalation and build up phases. Subjects will be randomized to receive active Chinese herbal formula or placebo. Subjects will be treated with OIT for 2 years and then food challenges will be performed to assess for desensitization. For those who achieve desensitization, all treatments will be discontinued and food challenges will be performed 3 months later to assess for sustained unresponsiveness.

Study Design

Study Type:
Actual Enrollment :
33 participants
Intervention Model:
Parallel Assignment
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Official Title:
Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of Chinese Herbal Therapy and Multiple Food Allergen Oral Immunotherapy
Actual Study Start Date :
Aug 20, 2016
Actual Primary Completion Date :
Jul 2, 2020
Actual Study Completion Date :
Feb 22, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active Comparator::Chinese Herbal Medication

Interventions: - Drug: Chinese Herbal Medication (E-B-FAHF-2), dose level was determined using the subject's weight at the screening visit (>20-30 kg = 5 capsules daily, >30-70 kg = 8 capsules daily, and >70 kg = 10 capsules daily)

Drug: Drug: Chinese Herbal Medication
Capsules, 26 month course, starting 2 months pre-OIT.
Other Names:
  • E-B-FAFH-2
  • Drug: Drug: Omalizumab
    4 months course, starting 2 months pre-OIT through the 2 month build-up phase
    Other Names:
  • Xolair®
  • Placebo Comparator: Placebo Comparator: Placebo

    Interventions: Drug: Placebo. Placebo capsules were identical in appearance but contained corn starch Drug: Omalizumab. Omalizumab was dosed as per the product insert Drug: Multi OIT. An initial rush dose to a maximum of 250 mg of protein of each allergen (total 270 mg of protein) and up-dosing every 2 weeks until the maintenance dose of 1000mg was reached.

    Drug: Drug: Placebo
    Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
    Other Names:
  • Placebo Chinese Herb
  • Outcome Measures

    Primary Outcome Measures

    1. Sustained unresponsiveness [29 months]

      Sustained unresponsiveness evaluated by the absence of dose-limiting symptoms to a cumulative dose of 4,444 mg protein.

    Secondary Outcome Measures

    1. Desensitization to 4444mg protein [26 months]

      Number of participants in the E-B-FAFH-2 group (EOIT) tolerating a cumulative dose of 4,4444mg of food allergen protein.

    2. High level desensitization to 7444mg protein or higher [26 months]

      Number of participants tolerating a cumulative dose of 7,444mg or higher (max of 10,444mg) to food allergen protein

    Eligibility Criteria


    Ages Eligible for Study:
    6 Years to 40 Years
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • 6 through 40 years

    • At least one of the following for each of the 3 study allergens: serum immunoglobulin E (IgE) >4000 U/L or skin -prick test >6mm

    • dose limiting symptoms at a cumulative dose of <=444 mg protein for 3 allergens as screening double-blind, placebo-controlled food challenge

    • use of an effective method of contraception by females of child-bearing potential

    • ability to ingest oat or corn with no allergic reaction

    Exclusion Criteria:
    • If baked milk or egg are tolerated (assessed by clinical report), then milk or egg may not be included as a study allergen

    • Any disorder in which epinephrine is contraindicated such as coronary artery disease, uncontrolled hypertension, and serious ventricular arrhythmias

    • History of other chronic disease requiring therapy (other than asthma, atopic dermatitis, or rhinitis)

    • History of eosinophilic gastrointestinal disease

    • Current participation in any other interventional study

    • Investigational drug use within 90 days

    • Subject is on build-up phase of any allergen immunotherapy (prior to maintenance dosing)

    • Current uncontrolled moderate to severe asthma as defined by:

    • Forced Expiratory Volume-1 (FEV1) value <80% predicted or any clinical features of moderate or severe persistent asthma baseline severity (as defined by the 2007 NHLBI Guidelines) and greater than high daily doses of inhaled corticosteroids (as defined for children and adults using dosing tables from the 2007 NHLBI Guidelines).

    • Use of steroid medications in the following manners: history of daily oral steroid dosing for >1 month during the past year, having 1 burst or steroid course within the past 6 months, or having >1 burst oral steroid course within the past 12 months.

    • Asthma requiring >1 hospitalization in the past year for asthma or >1 Emergency Department (ED) visit in the past 6 months for asthma.

    • Use of systemic steroid medications (Intravenous, Intramuscular or oral) for indications other than asthma for > 3 weeks within the past 6 months

    • Inability to discontinue antihistamines for the initial day of escalation, skin testing or DBPCFC

    • Use of Xolair® (omalizumab) within the past 6 months

    • Known sensitivity to Xolair® (omalizumab) or to the class of study drugs

    • Body weight more than 90 kg, or subjects with weight-IgE combination that yields a dose requirement greater than 600 mg dosing

    • Use of beta-blockers (oral), Angiotensinogen converting enzyme (ACE) inhibitors, angiotensin-receptor blockers or calcium channel blockers

    • Pregnancy or lactation

    • Inability to swallow placebo capsules

    • Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements

    Contacts and Locations


    No locations specified.

    Sponsors and Collaborators

    • New York Medical College
    • Icahn School of Medicine at Mount Sinai


    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    New York Medical College
    ClinicalTrials.gov Identifier:
    Other Study ID Numbers:
    • 02879006
    First Posted:
    Oct 27, 2023
    Last Update Posted:
    Oct 27, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 27, 2023